What The FDA Looks For When Inspecting Sites Soon After Approving Drugs
Quietly issued internal Compliance Program guidance on post-approval inspections suggests official action could be indicated when it turns out some “established conditions” are missing from applications. Whether the rate of these inspections will need to increase in the wake of the pandemic, particularly as applications for complex dosage forms and new manufacturing modalities multiply, remains to be seen.
You may also be interested in...
US FDA Balances Urgent Need For Platinum Chemotherapies Against Intas Plant’s Quality Failures
As politicians demand help for cancer-ridden constituents, the agency allows Indian plant that flunked inspection to resume exporting batches of cisplatin and carboplatin to the US, but only after passing independent 45-day batch certification reviews.
Why Generic Drug Manufacturing Is Faltering And Ways To Bolster It
Academic expert provides insight into the economic and quality challenges behind generic drug shortages, and what to do about it.
The Quality Lowdown: Blast From Past At Sun Mohali, Touch Of Future With IT/OT Integration
Ranbaxy consent decree is invoked again after the FDA’s latest inspection unveils backdating at Sun’s Mohali plant. FDA probes Intas plant’s many deceptions, Ipca stumbles on investigations without start dates and Sure-Biochem must admit missing client’s contamination.